Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 36,688 shares, a growth of 25.9% from the December 15th total of 29,141 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 94,355 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 94,355 shares, the short-interest ratio is currently 0.4 days. Approximately 0.7% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Revelation Biosciences in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC boosted its position in Revelation Biosciences, Inc. (NASDAQ:REVB) by 214.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 207,051 shares of the company’s stock after buying an additional 141,262 shares during the quarter. Revelation Biosciences makes up about 0.3% of Sabby Management LLC’s investment portfolio, making the stock its 16th biggest holding. Sabby Management LLC owned approximately 1.34% of Revelation Biosciences worth $294,000 at the end of the most recent reporting period. 12.80% of the stock is owned by institutional investors.

Revelation Biosciences Stock Up 5.5%

Shares of REVB traded up $0.05 during trading on Friday, reaching $0.95. The company’s stock had a trading volume of 76,649 shares, compared to its average volume of 89,457. The company has a fifty day moving average of $0.92 and a two-hundred day moving average of $1.68. Revelation Biosciences has a twelve month low of $0.76 and a twelve month high of $20.93. The company has a market cap of $5.62 million, a price-to-earnings ratio of -0.03 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.43). As a group, equities analysts forecast that Revelation Biosciences will post -49.33 EPS for the current fiscal year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.